Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Global, Open-Label, Multicenter, Phase 1/2 Study of the Safety and Dose Escalation of BAX 888, an Adeno-Associated Virus Serotype 8 (AAV8) Vector Expressing B-Domain Deleted Factor VIII (BDD-FVIII) in Severe Hemophilia A Subjects Administered a Single Intravenous Infusion

NCT03370172 is registered in ClinicalTrials.gov with Baxalta now part of Shire as lead sponsor.

NCT NCT03370172
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03370172 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Global, Open-Label, Multicenter, Phase 1/2 Study of the Safety and Dose Escalation of BAX 888, an Adeno-Associated Virus Serotype 8 (AAV8) Vector Expressing B-Domain Deleted Factor VIII (BDD-FVIII) in Severe Hemophilia A Subjects Administered a Single Intravenous Infusion
Lead sponsor
Baxalta now part of Shire
Phase
Phase 1/2
Overall status
Completed
Start date
February 27, 2018
Completion date
July 9, 2024
Enrollment
4 (actual)
Sites
26

Conditions

As the registry lists them; a condition with its own page is linked.

hemophilia a